Intervention

Chlorpromazine

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 5 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5

Recruiting0

Common conditions6

Lead sponsors shown5

Clinical trials

5 shown

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)NCT02600741 · 2015-07-24

COMPLETED

Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind EyeNCT01404364 · 2010-01-01

COMPLETED

Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic PatientsNCT00882518 · 2009-04-01

COMPLETED

Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic FeaturesNCT00202293 · 2001-10-01

COMPLETED

Clozapine Versus Chlorpromazine for Treatment-Unresponsive SchizophreniaNCT00169039 · 1994-12-01

TERMINATED

Common conditions

Schizophrenia3 Bipolar Disorder1 Blind Painful Eye1 Control of Pain Through Drug Injection1 Refractory Glaucoma1 Schizoaffective Disorder1

Leading sponsors

AstraZeneca 1 Harvard Medical School (HMS and HSDM) 1 Hospital Governador Celso Ramos 1 Janssen Scientific Affairs, LLC 1 Melbourne Health 1

Trial status mix

COMPLETED4

TERMINATED1

Phase mix

PHASE42

NA1

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.